Key result
Minor bleeding during direct oral anticoagulant therapy in patients with atrial fibrillation is not an absolute indication for drug discontinuation and requires assessment of modifiable risk factors.
Why the study?
DOACs increase bleeding risk in AF, but minor bleedings are not an absolute indication for withdrawal, prompting strategies for their management.
This review emphasizes that minor bleeding on DOACs should be managed by addressing modifiable risk factors and verifying correct dosing rather than inappropriately discontinuing anticoagulation.
Answers are grounded in this paper and cite their sources.
May support continuing DOACs after minor bleeding in AF once modifiable risks are addressed; leaves open need for randomized confirmation.
The recommended tactics for prevention of thromboembolic complications of atrial fibrillation (AF) is the oral anticoagulant (OAC) treatment. The drugs of choice for preventing stroke for most patients with AF, excluding some valvular defects, are direct OACs (DOACS). Regardless of the drug class, all anticoagulants, even at appropriate doses, increase the risk of bleeding. However, the development of minor bleedings is not an absolute indication for DOAC withdrawal. This review presents a tactics for management of patients with minor bleeding associated with the DOAC treatment.
No takes yet. Share an insight, caveat, or question.
A 2021 study conducted a review in Atrial fibrillation with minor bleeding. Direct oral anticoagulants (DOACs) vs. Vitamin K antagonists or no treatment (historical context) was evaluated. Minor bleeding during direct oral anticoagulant therapy in patients with atrial fibrillation is not an absolute indication for drug discontinuation and requires assessment of modifiable risk factors.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: